Steroid Expert Witnesses

This expert is a pharmacist and a pharmacologist and a former professor at Yale University and Georgetown University. He is also a former FDA Medical Officer/Senior Medical Analyst, who is an expert in the areas of drug Safety, drug development, regulatory affairs and FDA policy. He as also served as an advisor on the 2016 Ted Cruz presidential campaign, and has also been invited to testify in front of the U.S. Senate as a healthcare policy expert, FDA expert and Pharmacology expert. He has authored or co-authored over 50 publications, papers, articles, reviews, clinical protocols and reports in many related areas including FDA law, drug pricing, healthcare policy, healthcare insurance, drug development and drug patent law.

This highly qualified expert has years of experience in the field of neuropharmacology. He received his PhD degree from the University of California, Santa Barbara, and completed his fellowship training at Harvard University. He is a member of various professional associations, including the American Society of Pharmacology and Experimental Therapeutics and the American Chemical Society. He has published 250+ peer reviewed journal articles and has 51+ US issued patents that focus particularly on neurological studies. He also serves as the editor-in-chief for ACS Chemical Neuroscience, lectures both nationally and internationally and has received multiple honors for his outstanding work, including the John J. Abel award in pharmacology. He is the former co-director of the Synthesis Facility at the Vanderbilt Institute of Chemical Biology and the former senior organic chemist at Eli Lilly & Co. Currently, he is a professor of pharmacology and chemistry at a major university, where he is also the director of medicinal chemistry and DMPK at the Center for Neuroscience Drug Discovery. Additionally, he is the director of drug discovery at a major science institute in Tennessee.

This highly qualified expert earned his Bachelor's degree in Chemistry from the University of California Riverside and his PhD in Comparative Pharmacology and Toxicology from the University of California San Francisco. A member of numerous pharmaceutical societies, he is extremely well published, having authored 120+ peer-reviewed papers and 10 books. He previously served as an Assistant Professor of pharmacology at Washington State University and the University of Southern California. This expert currently serves as an Associate Professor at a top university medical center in southern California.

This qualified expert of Addiction Psychiatry completed his undergrad and MD in Canada at the McGill University. He completed his post-doc Residency and Fellowship in Psychiatry and Pharmacology in Canada at the University of Toronto. He is Board Certified in the US in Psychiatry & Neurology and in Addiction Psychiatry. He is a member of multiple Addiction Psychiatry Medical Associations and has published 200+ Publications on Addiction Psychiatry Research. He is currently a Professor of Psychiatry at a Top Medical University, the Director of a Top University's Addiction Center, and is the Chief Psychiatrist and Associate Medical Director at a Top University Hospital.

This expert's research career has been focused in the area of drug safety. As a clinical epidemiologist and pharmacologist, he uses large administrative databases in Canada and the United States as the main data source for his research. In the last ten years he has made significant contributions to this area quantifying rare drug adverse events with popular prescription drugs. His research has been used by the FDA, Health Canada and European Medicines Agency

This highly qualified expert has been conducting academic studies in toxicology for 30+ years. He completed his postdoctoral and fellowship training at Rochester University. He is a fellow at the American Association for the Advancement of the Sciences and a member of numerous professional associations, including the Academy of Toxicological Sciences, where he serves in the board of directors. He is also the past president of the International Neurotoxicology Association. He has authored approximately 300 peer-reviewed manuscripts and chapters in the area of neurotoxicology and serves on the editorial board of several journals. He is the former director of clinical pharmacology and toxicology at Vanderbilt and the former director of the NIEHS Molecular Toxicology Center. Currently, he is a professor and chair of molecular pharmacology at a major university in New York.

This highly qualified expert has years of experience in using animal models to study diabetes. He received his PhD degree from Ohio State University and completed his fellowship training in physiology and biophysics at the University of Illinois. He has published 98+ peer-reviewed journal articles and serves as a reviewer for 26+ renowned medical journals. He has been listed in "Who's Who in America" for science and engineering and lectures nationwide. Currently, he is a professor of pharmaceutical science and research and the director of pharmacology and toxicology at a major university. He is also the director of the Center for Diagnostic Nanosystems and the associate director of the Cell Differentiation and Development Center at the same institution. Additionally, he is the biological sciences laboratory supervisor at another major university.

This expert is board certified psychiatrist and addiction specialist, and also is certified by the American Board of Disability Analysts. He is an expert in handling capital, personal injury, loss mitigation, malpractice and negligence cases that involve the use of abused substances (especially, opiates, alcohol, hallucinogens, and stimulants), prescribed pharmacological agents, and in the general field of psychiatric and brain disease. This expert also is a leading neuroscientist and neuropsychopharmacologist. He can provide expert testimony on the effects of different brain states and function, in both health and disease, and their potential association with with legal culpability and liability. He currently serves as the Chairman of the Department of Psychiatry at a leading university in the USA, and has over 12 years experience as Chairman in Psychiatry Departments in the USA. His research focus is in the neuropsychopharmacology of addiction, addiction and pain, pain treatment, impact of genetics on human behavior, the basic, molecular, and the brain imaging sciences related to the functioning of the brain in health, disease and addiction. In recognition of his academic, scholarly and professional achievement, he is a Fellow of the Collegium Internationale Neuro-psychopharmacologicum and a Distinguished Fellow of the American Psychiatric Association. He is the recipient of numerous professional and scientific awards, including the Jack Mendelson Award at the NIH, which is awarded to individuals who have made distinguished contributions to our understanding of the science of addiction. He has an h-index of 46, and 11829 citations of his published work.

Medication Information Specialist with over 30 years of pharmaceutical experience in the areas of mental health comorbities, chronic pain management, psychiatric pharmacotherapy, pharmacoepidemiology, substance abuse, therapeutic medication monitoring, pharmaceutical marketing, illicit drug usage, adverse drug reactions, medication interactions, dietary and herbal supplements.

This highly qualified psychiatric pharmacology expert received a BS in Bacteriology from the Univeristy of California Los Angeles (UCLA) and earned his doctor of pharmacy (Pharm.D.) at the University of Southern California (USC). He had a National Institute of Mental Health (NMH) training fellowship in Psychiatric Pharmacy at the University of Nebraska Medical Center in Omaha, and was recruited to join the faculty of the highly-ranked The University of Texas at Austin College of Pharmacy. He is Board Certified in Psychiatric Pharmacy (BCPP) by the Board of Pharmaceutical Specialties. He serves on the Board of Directors for the College of Psychiatric and Neurologic Pharmacists Foundation and is a founding member of the College of Psychiatric and Neurologic Pharmacists (CPNP). During his 37 years career, this expert has provided clinical care and education in a variety of settings and treatment roles. He teaches didactic and experiential courses for Pharm.D. students and graduate courses for MS and PhD post-Pharm.D. students. He authored and successfully discussed with members of the Texas Legislature the creation of a clinical research unit at San Antonio State Hospital (SASH) that was funded by the Texas Legislature and jointly governed by the UT Austin College of Pharmacy, UT Health Science Center San Antonio Department of Psychiatry and SASH. This expert continues to publish scholarly articles and is regularly invited to do scholarly and lay presentations around the country on a variety of pharmacy and mental health related topics. He was the Senior Founding Editor for a major mental health publication. He edited Psychopharmacology Update newsletter from 1998-2002, and edited two editions of a compendium based upon this newsletter, Psychopharmacology Desktop Reference, published by Manisses Communications Group in 1999 and 2002. He has received several awards reflecting his accomplishments as a clinician, teacher, and researcher.

This expert is Board of Governors Professor in the Institute for Health, Health Care Policy and Aging Research and the School of Social Work for a leading NJ University. At the Institute, he directs the Center for Health Services Research on Pharmacotherapy, Chronic Disease Management, and Outcomes, whose programs include the AHRQ-funded Center for Education and Research on Mental Health Therapeutics. He also is Chair of the Institute's Division on Aging and Associate Institute Director for Health Services Research. His work, which has resulted in more than 250 publications, includes many widely cited books and research articles on old-age policy and services for the elderly; on the use and outcomes of psychotropic medications and other mental health treatments; on HIV/AIDS care; and on numerous other health care and social policy topics. His work on gerontological policy and inequality has been particularly influential nationally, as the cumulative advantage model of aging which he originally proposed in the 1980s and has developed in a line of subsequent work has contributed to understanding of late-life inequalities and the way in which initial advantages such as educational attainment; social structures; health and economic events over the lifecourse; and public policies interact to shape late-life outcomes. He has also been an important contributor to research on long-term care and mental health among the elderly. His work on mental health services has contributed importantly to understanding problems of healthcare access, quality and disparities in large usual care populations, particularly those served by Medicare and Medicaid. Much of his recent work has focused on prescription drug use in society where he has pioneered important studies on treatment use, safety, and effectiveness, including current work on comparative effectiveness of treatments funded by the FDA and the Agency for Healthcare Research and Quality. In 2009, his contributions to scholarship on health services and outcomes were recognized by his appointment as Board of Governors Professor of Health Services Research at a leading NJ University with the university's Board of Governors citing his "major theoretical, methodological, and research contributions in the fields of aging, HIV care, and behavioral health; his highly influential and social policy scholarship; the impressive rigor of his cross-disciplinary research contributions that have shaped thinking, both in the U.S. and abroad, on issues confronting some of the most vulnerable groups in our society" and for his "numerous and enormously influential books, journal articles, reports, and other publications . and his outstanding contributions to improving decision-making in public policy as evidenced by his frequent invitations to testify before and advise Congress and other policymakers."

This extremely qualified neurologist with over 20 years of experience, hundreds of publications and abstracts, author of multiple books is a leading pioneer in his field. He completed his medical education in Tunisia and then completed his residency in neurology at Temple university, where he was appointed chief resident during his third and fourth year in training. He is a member of multiple societies and a reviewer of numerous medical journals. His clinical, academic and research experience makes this candidate extremely well rounded to handle any neurology case. He currently works as an attending physician and researcher at a highly ranked university affiliated medical center.

This expert is a Board Certified in Psychiatry, with a background in pharmacology. He received is PhD in Pharmacology and his MD at Northwester University. He did his Psychiatry residency at Harvard Medical School and a fellowship in Geriatric Psychopharmacology at the National Institute of Mental Health. He has thirty years of experience practicing Geriatric Psychiatry/Psychopharmacology. He is among the early leaders in his field; he is credited with founding the Geriatric Psychiatry section, as well as a subspecialty training fellowship program at the University of Michigan, and has served, since 1997, as Editor-in-Chief of a geriatric neurology journal, and internationally recognized clinical research journal in the field. His research interests involves experimental pharmacotherapies in Alzheimer's disease and other dementias, course and outcomes of psychiatric illness in the elderly, and neurotransmitter function and pharmacotherapy in geriatric alcoholism. He is currently Associate Professor and Attending Physician at a major University. He has lectured widely on topics in Geriatric Psychiatry and has served as expert witness in malpractice and contested will cases.

This biomedical engineer specializes in materials science and biomechanics. He earned his B.S. and Ph.D. from New Jersey Institute of Technology, where he also served as a Postdoctoral Research Scientist overseeing the development and execution of experiments measuring neuronal activity after traumatic brain injuries. The expert is now an Adjunct Professor in Biomedical Engineering departments at two New Jersey higher education institutions.

This highly qualified expert earned his BS from George Fox University and PhD from University of California- Los Angeles. He completed a postdoctoral fellowship at The Scripps Research Institute. He is actively involved in research and education; to date he has 60+ original peer reviewed articles/ abstracts. Currently, he is an Assistant Professor of Pharmacology at a major university affiliated medical center. He has been trained in the study of drug discovery and taught on Molecular Pharmacology, Drug Discovery, Molecular Signaling/Transduction for the past few years at two medical schools. His research work includes collaborations with discovery teams to design new drug strategies, synthesize novel drugs, evaluate them in cell culture models, then evaluate their efficacy, side effect profiles, pharmacokinetics, and toxicology in animal models, all with the goal of developing new drugs for human treatment. Most of his research and drug development work is centered on developing new opioid and cannabinoid drugs for chronic pain, cancer treatment, and similar diseases.

This highly-qualified expert has her Masters, PhD and postdoctoral training in the area of environmental toxicology. She continues to work in this area, focusing primarily on the long term effects following exposures to halogenated hydrocarbons. In addition, her research activities involve the study of drug metabolism and nuclear hormone receptors. Her teaching activities (to dental, medical, graduate and undergraduate students), encompass the disciplines of toxicology and pharmacology. The focus here is understanding how exposures to certain chemicals (drugs or toxicants) elicit specific effects resulting in either therapeutic benefit or damage to certain tissues and how that impacts overall health.

This actively practicing, board certified toxicology specialist has assumed clinical positions in the field of toxicology and has published hundreds of articles and book chapters on the topic. Furthermore, he has also given nationally invited lectures on drug toxicity and is currently a faculty member at a major toxicology private practice.

This expert has been practicing toxicology for over 40 years. She holds a Master of Science in Clinical Chemistry as well as a Ph.D. in Toxicology, and an honorary doctoral degree in Medicine and Surgery from the Faculty of Medicine, University of Helsinki. She serves on the World Anti-Doping Agency's Prohibited List Committee, the National Commission on Forensic Sciences, the Organization of Scientific Area Committee on Toxicology, Transportation Research Board Committee on Alcohol and Other Drugs, and the National Safety Council's Alcohol, Drugs and Impairment Division Executive Board. She was a President of the International Association of Forensic Toxicologists, she is also a former President of the Society of Forensic Toxicologist and past Chair of the Toxicology Section of the American Academy of Forensic Sciences. She has published over 445 peer-reviewed articles and has presented more than 500 abstracts at national and international meetings, and she sits on the Editorial Board of multiple toxicological and chemical journals. She recently retired as Chief of Chemistry and Drug Metabolism, National Institute on Drug Abuse, National Institutes of Health. She serves as an Adjunct Professor at a major medical university. She consults with the US Department of Transportation, NMS Labs, and other diagnostic companies around the world. The journal Clinical Chemistry identified her as an inspiring mind.

This highly qualified environmental toxicologist specializing in mechanisms of action of dioxins and dioxin-like chemicals. After earned his PhD in Toxicology, this expert went on to hold numerous research roles, most notably at UC Davis. He is prominent in literature and as a presenter in the space. Currently, this expert is an Environmental Toxicology Research Scientist at a university in California.

This experienced expert received his BS in Chemistry, his MS in Pathology, and his MD from Dalhousie University. He completed his residency in Anesthesia at Dalhousie University and his research fellowship in Clinical Pharmacology in Anesthesia at Stanford University. He has published over 65 peer reviewed articles, 78 abstracts, and has been invited to present 18 presentations. Formerly, he was a clinical instructor of anesthesia and a staff physician at Stanford University. Currently, he is a professor of anesthesia at a prestigious university and is part of the medical staff at a top medical center in California.